Correlation Engine 2.0
Clear Search sequence regions


  • accounts (1)
  • and disease (2)
  • aspirin (2)
  • asthma (5)
  • benchmark (1)
  • biologics (16)
  • ci 2 (2)
  • ci 4 (1)
  • comorbid (2)
  • corticosteroids (12)
  • diagnosis (1)
  • eosinophilia (1)
  • eosinophils (1)
  • essential (1)
  • expert opinion (1)
  • factors (2)
  • focus (1)
  • food (3)
  • health care cost (1)
  • IL 13 (1)
  • il 4 (1)
  • il- 13 receptors (1)
  • il5 (1)
  • impaired (1)
  • inform patient (1)
  • mepolizumab (4)
  • meta analysis (1)
  • nasal (7)
  • nasal polyps (31)
  • nasal symptom (1)
  • nose (2)
  • omalizumab (5)
  • patient preferences (3)
  • patients (26)
  • period (1)
  • phase (8)
  • physicians (2)
  • placebo (5)
  • polyp (15)
  • polyp size (1)
  • research (2)
  • risk benefit (1)
  • risk factors (2)
  • rna (1)
  • safety (3)
  • serum (1)
  • sinuses (4)
  • smell (4)
  • synapse (1)
  • therapies (1)
  • weight (1)
  • western world (1)
  • xolair (1)
  • Sizes of these terms reflect their relevance to your search.

    Biologic therapy is a new treatment option for patients with chronic rhinosinusitis with nasal polyps (CRSwNP). Currently, the only biologic with Food and Drug Administration-approval status for CRSwNP is dupilumab. Several other biologics are likely to be approved for CRSwNP, including mepolizumab and omalizumab, based on their promising phase 3 trial results. The role of biologics in the treatment paradigm requires consideration of multiple factors that have yet to be clearly established. This includes identifying patients most appropriate for biologic therapy while considering long-term safety and cost-effectiveness in the context of patient preferences and goals.

    Citation

    Gayatri B Patel, Anju T Peters. The Role of Biologics in Chronic Rhinosinusitis With Nasal Polyps. Ear, nose, & throat journal. 2020 Oct 09;100(1):44-47


    PMID: 33035132

    View Full Text